Inhibition of telomerase activity preferentially targets aldehyde dehydrogenase-positive cancer stem-like cells in lung cancer

Molecular Cancer

Volumn 10, Issue , 2011, Pages

  Serrano, Diego ^a,b   Bleau, Anne Marie ^a   Fernandez Garcia, Ignacio ^a   Fernandez Marcelo, Tamara ^c   Iniesta, Pilar ^c   Ortiz de Solorzano, Carlos ^a   Calvo, Alfonso ^a,b  

^a UNIVERSITY OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

^c UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

Author keywords

ALDH activity; Cancer stem cells; Lung cancer; Telomerase

Indexed keywords

ALDEHYDE DEHYDROGENASE; ATM PROTEIN; HISTONE H2AX; MST 312; PROTEIN P21; PROTEIN P27; TELOMERASE; TELOMERASE INHIBITOR; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER INHIBITION; CANCER RADIOTHERAPY; CANCER STEM CELL; CELL CYCLE G2 PHASE; CELL CYCLE M PHASE; CELL ISOLATION; CONTROLLED STUDY; DNA DAMAGE; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG SENSITIVITY; ENZYME ACTIVITY; ENZYME INHIBITION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PHENOTYPE; TELOMERE; TUMOR VOLUME; TUMOR XENOGRAFT; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; DRUG SCREENING; LUNG TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; MOUSE MUTANT; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHYSIOLOGY; TRANSGENIC MOUSE; TUMOR CELL LINE;

ALDEHYDE DEHYDROGENASE; ANIMALS; ANTINEOPLASTIC AGENTS; BENZAMIDES; CARCINOMA, NON-SMALL-CELL LUNG; CELL LINE, TUMOR; ENZYME INHIBITORS; HUMANS; LUNG NEOPLASMS; MALE; MICE; MICE, INBRED NOD; MICE, SCID; MICE, TRANSGENIC; MOLECULAR TARGETED THERAPY; NEOPLASTIC STEM CELLS; TELOMERASE; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 80052264525     PISSN: None     EISSN: 14764598     Source Type: Journal    
DOI: 10.1186/1476-4598-10-96     Document Type: Article

References (43)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249. 10.3322/caac.20006, 19474385.
2. Dallas NA, Xia L, Fan F, Gray MJ, Gaur P, van Buren G, Samuel S, Kim MP, Lim SJ, Ellis LM. Chemoresistant colorectal cancer cells, the cancer stem cell phenotype, and increased sensitivity to insulin-like growth factor-I receptor inhibition. Cancer Res 2009, 69:1951-1957. 10.1158/0008-5472.CAN-08-2023, 19244128.
3. Bortolomai I, Canevari S, Facetti I, De Cecco L, Castellano G, Zacchetti A, Alison MR, Miotti S. Tumor initiating cells: Development and critical characterization of a model derived from the A431 carcinoma cell line forming spheres in suspension. Cell Cycle 2010, 9.
4. Shafee N, Smith CR, Wei S, Kim Y, Mills GB, Hortobagyi GN, Stanbridge EJ, Lee EY. Cancer stem cells contribute to cisplatin resistance in Brca1/p53-mediated mouse mammary tumors. Cancer Res 2008, 68:3243-3250. 10.1158/0008-5472.CAN-07-5480, 2929908, 18451150.
5. Bertolini G, Roz L, Perego P, Tortoreto M, Fontanella E, Gatti L, Pratesi G, Fabbri A, Andriani F, Tinelli S, et al. Highly tumorigenic lung cancer CD133+ cells display stem-like features and are spared by cisplatin treatment. Proc Natl Acad Sci USA 2009, 106:16281-16286. 10.1073/pnas.0905653106, 2741477, 19805294.
6. Nishide K, Nakatani Y, Kiyonari H, Kondo T. Glioblastoma formation from cell population depleted of Prominin1-expressing cells. PLoS One 2009, 4:e6869. 10.1371/journal.pone.0006869, 2729925, 19718438.
7. Meng X, Li M, Wang X, Wang Y, Ma D. Both CD133+ and CD133- subpopulations of A549 and H446 cells contain cancer-initiating cells. Cancer Sci 2009, 100:1040-1046. 10.1111/j.1349-7006.2009.01144.x, 19385971.
8. Ho MM, Ng AV, Lam S, Hung JY. Side population in human lung cancer cell lines and tumors is enriched with stem-like cancer cells. Cancer Res 2007, 67:4827-4833. 10.1158/0008-5472.CAN-06-3557, 17510412.
9. Bleau AM, Huse JT, Holland EC. The ABCG2 resistance network of glioblastoma. Cell Cycle 2009, 8:2936-2944.
10. Vasiliou V, Pappa A, Petersen DR. Role of aldehyde dehydrogenases in endogenous and xenobiotic metabolism. Chem Biol Interact 2000, 129:1-19. 10.1016/S0009-2797(00)00211-8, 11154732.
11. Chute JP, Muramoto GG, Whitesides J, Colvin M, Safi R, Chao NJ, McDonnell DP. Inhibition of aldehyde dehydrogenase and retinoid signaling induces the expansion of human hematopoietic stem cells. Proc Natl Acad Sci USA 2006, 103:11707-11712. 10.1073/pnas.0603806103, 1544234, 16857736.
12. Huang EH, Hynes MJ, Zhang T, Ginestier C, Dontu G, Appelman H, Fields JZ, Wicha MS, Boman BM. Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. Cancer Res 2009, 69:3382-3389. 10.1158/0008-5472.CAN-08-4418, 2789401, 19336570.
13. Jiang F, Qiu Q, Khanna A, Todd NW, Deepak J, Xing L, Wang H, Liu Z, Su Y, Stass SA, Katz RL. Aldehyde dehydrogenase 1 is a tumor stem cell-associated marker in lung cancer. Mol Cancer Res 2009, 7:330-338. 10.1158/1541-7786.MCR-08-0393, 19276181.
14. Su Y, Qiu Q, Zhang X, Jiang Z, Leng Q, Liu Z, Stass SA, Jiang F. Aldehyde dehydrogenase 1 A1-positive cell population is enriched in tumor-initiating cells and associated with progression of bladder cancer. Cancer Epidemiol Biomarkers Prev 2010, 19:327-337. 10.1158/1055-9965.EPI-09-0865, 20142235.
15. Charafe-Jauffret E, Ginestier C, Iovino F, Tarpin C, Diebel M, Esterni B, Houvenaeghel G, Extra JM, Bertucci F, Jacquemier J, et al. Aldehyde dehydrogenase 1-positive cancer stem cells mediate metastasis and poor clinical outcome in inflammatory breast cancer. Clin Cancer Res 2010, 16:45-55. 10.1158/1078-0432.CCR-09-1630, 2874875, 20028757.
16. Bailey SM, Murnane JP. Telomeres, chromosome instability and cancer. Nucleic Acids Res 2006, 34:2408-2417. 10.1093/nar/gkl303, 1458522, 16682448.
17. Harley CB. Telomere loss: mitotic clock or genetic time bomb?. Mutat Res 1991, 256:271-282.
18. Artandi SE, DePinho RA. A critical role for telomeres in suppressing and facilitating carcinogenesis. Curr Opin Genet Dev 2000, 10:39-46. 10.1016/S0959-437X(99)00047-7, 10679392.
19. Ben-Porath I, Weinberg RA. The signals and pathways activating cellular senescence. Int J Biochem Cell Biol 2005, 37:961-976. 10.1016/j.biocel.2004.10.013, 15743671.
20. Collins K. Physiological assembly and activity of human telomerase complexes. Mech Ageing Dev 2008, 129:91-98. 10.1016/j.mad.2007.10.008, 2323683, 18054989.
21. Blasco MA. Telomerase beyond telomeres. Nat Rev Cancer 2002, 2:627-633. 10.1038/nrc862, 12154355.
22. Lantuejoul S, Raynaud C, Salameire D, Gazzeri S, Moro-Sibilot D, Soria JC, Brambilla C, Brambilla E. Telomere maintenance and DNA damage responses during lung carcinogenesis. Clin Cancer Res 2010, 16:2979-2988. 10.1158/1078-0432.CCR-10-0142, 20404006.
23. Sullivan JP, Spinola M, Dodge M, Raso MG, Behrens C, Gao B, Schuster K, Shao C, Larsen JE, Sullivan LA, et al. Aldehyde dehydrogenase activity selects for lung adenocarcinoma stem cells dependent on notch signaling. Cancer Res 2010, 70:9937-9948. 10.1158/0008-5472.CAN-10-0881, 21118965.
24. Seimiya H, Oh-hara T, Suzuki T, Naasani I, Shimazaki T, Tsuchiya K, Tsuruo T. Telomere shortening and growth inhibition of human cancer cells by novel synthetic telomerase inhibitors MST-312, MST-295, and MST-1991. Mol Cancer Ther 2002, 1:657-665.
25. Rich JN. Cancer stem cells in radiation resistance. Cancer Res 2007, 67:8980-8984. 10.1158/0008-5472.CAN-07-0895, 17908997.
26. Wong VC, Ma J, Hawkins CE. Telomerase inhibition induces acute ATM-dependent growth arrest in human astrocytomas. Cancer Lett 2009, 274:151-159. 10.1016/j.canlet.2008.09.012, 18945545.
27. Charafe-Jauffret E, Ginestier C, Iovino F, Wicinski J, Cervera N, Finetti P, Hur MH, Diebel ME, Monville F, Dutcher J, et al. Breast cancer cell lines contain functional cancer stem cells with metastatic capacity and a distinct molecular signature. Cancer Res 2009, 69:1302-1313. 10.1158/0008-5472.CAN-08-2741, 2819227, 19190339.
28. Ucar D, Cogle CR, Zucali JR, Ostmark B, Scott EW, Zori R, Gray BA, Moreb JS. Aldehyde dehydrogenase activity as a functional marker for lung cancer. Chem Biol Interact 2009, 178:48-55. 10.1016/j.cbi.2008.09.029, 2976869, 18952074.
29. Marian CO, Cho SK, McEllin BM, Maher EA, Hatanpaa KJ, Madden CJ, Mickey BE, Wright WE, Shay JW, Bachoo RM. The telomerase antagonist, imetelstat, efficiently targets glioblastoma tumor-initiating cells leading to decreased proliferation and tumor growth. Clin Cancer Res 2010, 16:154-163. 10.1158/1078-0432.CCR-09-2850, 2883447, 20048334.
30. Lantuejoul S, Salon C, Soria JC, Brambilla E. Telomerase expression in lung preneoplasia and neoplasia. Int J Cancer 2007, 120:1835-1841. 10.1002/ijc.22473, 17311257.
31. Philippi C, Loretz B, Schaefer UF, Lehr CM. Telomerase as an emerging target to fight cancer--opportunities and challenges for nanomedicine. Journal of controlled release: official journal of the Controlled Release Society 2010, 146:228-240.
32. Molckovsky A, Siu LL. First-in-class, first-in-human phase I results of targeted agents: highlights of the 2008 American society of clinical oncology meeting. J Hematol Oncol 2008, 1:20. 10.1186/1756-8722-1-20, 2647552, 18959794.
33. Dikmen ZG, Gellert GC, Jackson S, Gryaznov S, Tressler R, Dogan P, Wright WE, Shay JW. In vivo inhibition of lung cancer by GRN163L: a novel human telomerase inhibitor. Cancer Res 2005, 65:7866-7873.
34. Hochreiter AE, Xiao H, Goldblatt EM, Gryaznov SM, Miller KD, Badve S, Sledge GW, Herbert BS. Telomerase template antagonist GRN163L disrupts telomere maintenance, tumor growth, and metastasis of breast cancer. Clin Cancer Res 2006, 12:3184-3192. 10.1158/1078-0432.CCR-05-2760, 16707619.
35. Goldblatt EM, Gentry ER, Fox MJ, Gryaznov SM, Shen C, Herbert BS. The telomerase template antagonist GRN163L alters MDA-MB-231 breast cancer cell morphology, inhibits growth, and augments the effects of paclitaxel. Mol Cancer Ther 2009, 8:2027-2035. 10.1158/1535-7163.MCT-08-1188, 19509275.
36. Kraemer K, Fuessel S, Schmidt U, Kotzsch M, Schwenzer B, Wirth MP, Meye A. Antisense-mediated hTERT inhibition specifically reduces the growth of human bladder cancer cells. Clin Cancer Res 2003, 9:3794-3800.
37. Mikami-Terao Y, Akiyama M, Yuza Y, Yanagisawa T, Yamada O, Yamada H. Antitumor activity of G-quadruplex-interactive agent TMPyP4 in K562 leukemic cells. Cancer Lett 2008, 261:226-234. 10.1016/j.canlet.2007.11.017, 18096315.
38. Seimiya H, Muramatsu Y, Ohishi T, Tsuruo T. Tankyrase 1 as a target for telomere-directed molecular cancer therapeutics. Cancer Cell 2005, 7:25-37. 10.1016/j.ccr.2004.11.021, 15652747.
39. Cawthon RM. Telomere measurement by quantitative PCR. Nucleic Acids Res 2002, 30:e47. 10.1093/nar/30.10.e47, 115301, 12000852.
40. Garcia-Aranda C, de Juan C, Diaz-Lopez A, Sanchez-Pernaute A, Torres AJ, Diaz-Rubio E, Balibrea JL, Benito M, Iniesta P. Correlations of telomere length, telomerase activity, and telomeric-repeat binding factor 1 expression in colorectal carcinoma. Cancer 2006, 106:541-551. 10.1002/cncr.21625, 16388518.
41. Ginestier C, Hur MH, Charafe-Jauffret E, Monville F, Dutcher J, Brown M, Jacquemier J, Viens P, Kleer CG, Liu S, et al. ALDH1 is a marker of normal and malignant human mammary stem cells and a predictor of poor clinical outcome. Cell Stem Cell 2007, 1:555-567. 10.1016/j.stem.2007.08.014, 2423808, 18371393.
42. Chin K, de Solorzano CO, Knowles D, Jones A, Chou W, Rodriguez EG, Kuo WL, Ljung BM, Chew K, Myambo K, et al. In situ analyses of genome instability in breast cancer. Nat Genet 2004, 36:984-988. 10.1038/ng1409, 15300252.
43. Munoz-Barrutia A, Garcia-Munoz J, Ucar B, Fernandez-Garcia I, Ortiz-de-Solorzano C. Blind spectral unmixing of M-FISH images by non-negative matrix factorization. Conf Proc IEEE Eng Med Biol Soc 2007, 2007:6248-6251.